Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LithuaniaBack to Lithuania

Clinical trials in Siauliai

24 clinical trials in Siauliai, Lithuania. Every trial is listed in the EU Clinical Trials Register and updated daily.

LithuaniaOur site in LithuaniaKlinikiniai-Tyrimai.lt(opens in a new tab)
Siauliai at a glance
24
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

24 trials in Siauliai

Open in trial search

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Cardiac failure chronic+1

Recruiting

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Pharmacosmos A/S

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Rheumatoid arthritis

Not yet recruiting

Study on the Effectiveness and Safety of Tocilizumab and Methotrexate for Adults with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Dr Reddy's Laboratories Limited

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Other cities in Lithuania

The busiest research cities in the country

All 10 cities in Lithuania

Clinical research in Siauliai

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on cardiovascular disease prevention and treatment, including studies of new medications for stroke prevention and heart attack management.

  • Stroke Prevention in Atrial Fibrillation
  • Acute Myocardial Infarction Treatment
  • Atherosclerotic Disease Management

Groundbreaking research evaluating novel compounds like asundexian and inclisiran for cardiovascular protection.

02 Autoimmune Conditions

Comprehensive studies addressing various autoimmune disorders, with particular focus on innovative therapeutic approaches.

  • Rheumatoid Arthritis Treatment
  • Psoriatic Arthritis Management
  • Sjögren's Syndrome Therapy

Advanced trials testing new biological agents and biosimilars for improved disease control.

03 Neurological Studies

Leading-edge research in multiple sclerosis and related neurological conditions, exploring new treatment pathways.

  • Multiple Sclerosis Therapies
  • Long-term Treatment Safety
  • Disease-Modifying Treatments

Evaluating innovative medications like remibrutinib and tolebrutinib for enhanced therapeutic outcomes.

04 Metabolic Disorders

Research focusing on lipid disorders and metabolic conditions, investigating novel therapeutic approaches.

  • Hypertriglyceridemia Management
  • Lipid Level Control
  • Metabolic Disease Treatment

Studies evaluating new compounds for managing severe metabolic conditions.

Back to LithuaniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.